Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

Recruiting now · Phase 4

Conditions studied: Early PCSK9 Inhibitor on Ventricular Remodling

In brief

This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.

Key facts

Study ID: NCT04731155
Run by: Shanghai Tong Ren Hospital
People needed: 20
Starts: 2021-04-12
Expected to finish: 2025-10-01
Last updated by the study team: 2025-05-21

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject must be at least 18 years of age and less than 80 years old
Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for AMI and LAD should be the only culprit vessel.
Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure

You may not qualify if…

Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
Known hypersensitivity or contraindication to study medications
Plan to receive revascularization in next six month.
Have received revascularization before.
Subjects with life expectation less than one year.
Subjects with active malignant tumor
subjects with severe liver or renal dysfunction（ALT >5倍ULA，eGFR<15ml/min/1.73mm2）
Other conditions which the investigators think not applicable to the study.

Where it is running

Tongren Hospital, Shanghai — Shanghai, Shanghai Municipality, China (enrolling)
Shanghai tenth people's hospital — Shanghai, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.